BIOA Stock Overview
A clinical-stage biopharmaceutical company that develops therapeutic product candidates for metabolic diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
BioAge Labs, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$19.14 |
| 52 Week High | US$26.62 |
| 52 Week Low | US$18.00 |
| Beta | 0 |
| 11 Month Change | -20.45% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 4.53% |
Recent News & Updates
Shareholder Returns
| BIOA | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 5.6% | 1.6% | 2.2% |
| 1Y | n/a | 9.9% | 31.6% |
Return vs Industry: Insufficient data to determine how BIOA performed against the US Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how BIOA performed against the US Market.
Price Volatility
| BIOA volatility | |
|---|---|
| BIOA Average Weekly Movement | 12.6% |
| Pharmaceuticals Industry Average Movement | 9.5% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: BIOA's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine BIOA's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 59 | Kristen Fortney | bioagelabs.com |
BioAge Labs, Inc. is a clinical-stage biopharmaceutical company that develops therapeutic product candidates for metabolic diseases. The company’s technology platform and differentiated human datasets allows users to identify targets based on insights into molecular changes that drive aging. Its product includes azelaprag, an orally available small molecule that is in phase 1 clinical trial for the treatment of obesity; and initiated phase 2 clinical trial of azelaprag in combination with tirzepatide for the treatment of obesity in older adults.
BioAge Labs, Inc. Fundamentals Summary
| BIOA fundamental statistics | |
|---|---|
| Market cap | US$686.14m |
| Earnings (TTM) | -US$70.94m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-9.7x
P/E RatioIs BIOA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BIOA income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$70.94m |
| Earnings | -US$70.94m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.98 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 3.2% |
How did BIOA perform over the long term?
See historical performance and comparison